Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms

References

• Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K. Engineering the variable region of therapeutic IgG antibodies. Mabs-Austin 2011; 3:243-52; PMID:21406966; https://doi.org/10.4161/mabs.3.3.15234
   PubMed Web of Science ®Google Scholar
• Klein C, Schaefer W, Regula JT. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. Mabs-Austin 2016; 8:1010-20; PMID:27285945; https://doi.org/10.1080/19420862.2016.1197457
   PubMed Web of Science ®Google Scholar
• Nelson AL. Antibody fragments Hope and hype. Mabs-Austin 2010; 2:77-83; PMID:20093855; https://doi.org/10.4161/mabs.2.1.10786
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Half-life extended biotherapeutics. Expert Opin Biol Th 2016; 16:903-15; PMID:26967759; https://doi.org/10.1517/14712598.2016.1165661
   PubMed Web of Science ®Google Scholar
• Ayyar BV, Arora S, O'Kennedy R. Coming-of-Age of Antibodies in Cancer Therapeutics. Trends Pharmacol Sci 2016; 37:1009-28; PMID:27745709; https://doi.org/10.1016/j.tips.2016.09.005
   PubMed Web of Science ®Google Scholar
• Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; https://doi.org/10.1038/nri2747
   PubMed Web of Science ®Google Scholar
• Mimoto F, Kuramochi T, Katada H, Igawa T, Hattori K. Fc engineering to improve the function of therapeutic antibodies. Curr Pharm Biotechnol 2016; 17:1298-1314; PMID:27552846; https://doi.org/0.2174/1389201017666160824161854
   PubMed Web of Science ®Google Scholar
• Li B, Tesar D, Boswell CA, Cahaya HS, Wong A, Zhang JH, Meng YG, Eigenbrot C, Pantua H, Diao JY, et al. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. Mabs-Austin 2014; 6:1255-64; PMID:25517310; https://doi.org/10.4161/mabs.29809
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Lu JR, Witcher DR, Leung D, Tang Y, Wroblewski VJ. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. Mabs-Austin 2015; 7:1084-93; PMID:26337808; https://doi.org/10.1080/19420862.2015.1075109
   PubMed Web of Science ®Google Scholar
• Leavy O. Therapeutic antibodies: past, present and future. Nat Rev Immunol 2010; 10:297; PMID:20422787; https://doi.org/10.1038/nri2763
   PubMed Web of Science ®Google Scholar
• Sand KMK, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT. Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol 2015; 5:1-21; PMID:25674083; https://doi.org/10.3389/fimmu.2014.00682
   PubMed Web of Science ®Google Scholar
• Martins JP, Kennedy PJ, Santos HA, Barrias C, Sarmento B. A comprehensive review of the neonatal Fc receptor and its application in drug delivery. Pharmacol Therapeut 2016; 161:22-39; PMID:27016466; https://doi.org/10.1016/j.pharmthera.2016.03.007
   PubMed Web of Science ®Google Scholar
• Giragossian C, Clark T, Piche-Nicholas N, Bowman CJ. Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-Based biotherapeutics. Curr Drug Metab 2013; 14:764-90; PMID:23952252; https://doi.org/10.2174/13892002113149990099
   PubMed Web of Science ®Google Scholar
• Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J, et al. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. Mabs-Austin 2013; 5:576-86; PMID:23765230; https://doi.org/10.4161/mabs.24981
   PubMed Web of Science ®Google Scholar
• Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. Mabs-Austin 2015; 7:331-43; PMID:25658443; https://doi.org/10.1080/19420862.2015.1008353
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall'Acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. A novel investigational Fc-Modified humanized monoclonal antibody, motavizumab-YTE, has an extended Half-Life in healthy adults. Antimicrob Agents Ch 2013; 57:6147-53; PMID:24080653; https://doi.org/10.1128/AAC.01285-13
   PubMed Web of Science ®Google Scholar
• Dall'Acqua WF, Kiener PA, Wu HR. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514-24; PMID:16793771; https://doi.org/10.1074/jbc.M604292200
   PubMed Web of Science ®Google Scholar
• Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. Mabs-Austin 2011; 3:422-30; PMID:22048693; https://doi.org/10.4161/mabs.3.5.16983
   PubMed Web of Science ®Google Scholar
• Souders CA, Nelson SC, Wang Y, Crowley AR, Klempner MS, Thomas W, Jr. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. mAbs 2015; 7:912-21; PMID:26018774; https://doi.org/10.1080/19420862.2015.1054585
   PubMed Web of Science ®Google Scholar
• Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data What have we learned? Mabs-Austin 2011; 3:61-6; PMID:20962582; https://doi.org/10.4161/mabs.3.1.13799
   PubMed Web of Science ®Google Scholar
• Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA. Quantitative prediction of human pharmacokinetics for monoclonal antibodies retrospective analysis of monkey as a single species for First-in-Human prediction. Clin Pharmacokinet 2011; 50:131-42; PMID:21241072; https://doi.org/10.2165/11537430-000000000-00000
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu JR, Witcher DR, Wroblewski VJ. FcRn Affinity-Pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab Dispos 2012; 40:1545-55; PMID:22584253; https://doi.org/10.1124/dmd.112.045864
   PubMed Web of Science ®Google Scholar
• Gurbaxani B, Dela Cruz LL, Chintalacharuvu K, Morrison SL. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol 2006; 43:1462-73; PMID:16139891; https://doi.org/10.1016/j.molimm.2005.07.032
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu J, Witcher DR, Wroblewski VJ. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab Dispos 2012; 40:1545-55; PMID:22584253; https://doi.org/10.1124/dmd.112.045864
   PubMed Web of Science ®Google Scholar
• Tesar DB, Tiangco NE, Bjorkman PJ. Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor. Traffic 2006; 7:1127-42; PMID:17004319; https://doi.org/10.1111/j.1600-0854.2006.00457.x
   PubMed Web of Science ®Google Scholar
• Praetor A, Ellinger I, Hunziker W. Intracellular traffic of the MHC class I-like IgG Fc receptor, FcRn, expressed in epithelial MDCK cells. J Cell Sci 1999; 112:2291-9; PMID:10381385.
   PubMed Web of Science ®Google Scholar
• Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13:1551-9; PMID:11717196; https://doi.org/10.1093/intimm/13.12.1551
   PubMed Web of Science ®Google Scholar
• Martin WL, West AP, Jr., Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 2001; 7:867-77; PMID:11336709; https://doi.org/10.1016/S1097-2765(01)00230-1
   PubMed Web of Science ®Google Scholar
• Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: Impact on PK/PD and efficacy. Aaps J 2012; 14:296-302; PMID:22407289; https://doi.org/10.1208/s12248-012-9340-y
   PubMed Web of Science ®Google Scholar
• Hotzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. Mabs-Austin 2012; 4:753-60; PMID:23778268; https://doi.org/10.4161/mabs.22189
   PubMed Web of Science ®Google Scholar
• Russell WM. The development of the three Rs concept. Altern Lab Anim 1995; 23:298-304; PMID:11656565.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715-25; PMID:17703228; https://doi.org/10.1038/nri2155
   PubMed Web of Science ®Google Scholar
• Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: Implications for therapeutic antibodies. Int Immunol 2001; 13:1551-9; PMID:11717196; https://doi.org/10.1093/intimm/13.12.1551
   PubMed Web of Science ®Google Scholar
• Vaccaro C, Bawdon R, Wanjie S, Ober RJ, Ward ES. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. P Natl Acad Sci USA 2006; 103:18709-14; PMID:17116867; https://doi.org/10.1073/pnas.0606304103
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Lu J, Witcher DR, Leung D, Tang Y, Wroblewski VJ. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. mAbs 2015; 7:1084-93; PMID:26337808; https://doi.org/10.1080/19420862.2015.1075109
   PubMed Web of Science ®Google Scholar
• Grevys A, Bern M, Foss S, Brodie DB, Moen A, Gunnarsen KS, Aase A, Michaelsen TE, Sandlie I, Andersen JT. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions. J Immunol 2015; 194:5497-508; PMID:25904551; https://doi.org/10.4049/jimmunol.1401218
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. mAbs 2015; 7:483-93; PMID:25695748; https://doi.org/10.1080/19420862.2015.1016696
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010; 23:385-92; PMID:20159773; https://doi.org/10.1093/protein/gzq009
   PubMed Web of Science ®Google Scholar